Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Bifunctional ligand design for modulating mutant p53 aggregation in cancer.

Miller JJ, Blanchet A, Orvain C, Nouchikian L, Reviriot Y, Clarke RM, Martelino D, Wilson D, Gaiddon C, Storr T.

Chem Sci. 2019 Oct 7;10(46):10802-10814. doi: 10.1039/c9sc04151f. eCollection 2019 Dec 14.

2.

HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.

Spaety ME, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C, Yanagihara K, Okamoto K, Jung AC, Mellitzer G, Pfeffer S, Gaiddon C.

Cancers (Basel). 2019 Nov 7;11(11). pii: E1747. doi: 10.3390/cancers11111747.

3.

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC.

Coliat P, Ramolu L, Jégu J, Gaiddon C, Jung AC, Pencreach E.

Cancers (Basel). 2019 Oct 21;11(10). pii: E1607. doi: 10.3390/cancers11101607.

4.

Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway.

Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, Huang X, Hou Y, Zhu D, Zou H, Gu Y, Weng X, Wang Y, Li Y, Wu T, Yao M, Gross I, Gaiddon C, Luo M, Wang J, Meng X.

Oncogene. 2020 Jan;39(2):469-485. doi: 10.1038/s41388-019-1035-8. Epub 2019 Oct 9.

5.

Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction.

Job S, Reyniès A, Heller B, Weiss A, Guérin E, Macabre C, Ledrappier S, Bour C, Wasylyk C, Etienne-Selloum N, Brino L, Gaiddon C, Wasylyk B, Jung AC.

Cancers (Basel). 2019 Jun 8;11(6). pii: E795. doi: 10.3390/cancers11060795.

6.

Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation.

Santoro A, Vileno B, Palacios Ò, Peris-Díaz MD, Riegel G, Gaiddon C, Krężel A, Faller P.

Metallomics. 2019 May 22;11(5):994-1004. doi: 10.1039/c9mt00061e.

PMID:
31011727
7.

From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents.

Lam NYS, Truong D, Burmeister H, Babak MV, Holtkamp HU, Movassaghi S, Ayine-Tora DM, Zafar A, Kubanik M, Oehninger L, Söhnel T, Reynisson J, Jamieson SMF, Gaiddon C, Ott I, Hartinger CG.

Inorg Chem. 2018 Nov 19;57(22):14427-14434. doi: 10.1021/acs.inorgchem.8b02634. Epub 2018 Nov 8.

PMID:
30406647
8.

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Cerón-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C.

Cancer Lett. 2019 Jan;440-441:145-155. doi: 10.1016/j.canlet.2018.09.029. Epub 2018 Oct 17.

PMID:
30339780
9.

Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.

Miller JJ, Orvain C, Jozi S, Clarke RM, Smith JR, Blanchet A, Gaiddon C, Warren JJ, Storr T.

Chemistry. 2018 Dec 3;24(67):17734-17742. doi: 10.1002/chem.201802677. Epub 2018 Nov 9.

PMID:
30230059
10.

Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes.

Chow MJ, Babak MV, Tan KW, Cheong MC, Pastorin G, Gaiddon C, Ang WH.

Mol Pharm. 2018 Aug 6;15(8):3020-3031. doi: 10.1021/acs.molpharmaceut.8b00003. Epub 2018 Jul 20.

PMID:
29979603
11.

Use of a case-mix approach to study the trends in the incidence of second primary cancers.

Gass B, Marrer E, Bara S, Ligier K, Molinié F, Colonna M, Daubisse-Marliac L, Trétarre B, Lapôtre-Ledoux B, Woronoff AS, Guizard AV, Bouvier V, Troussard X, Gaiddon C, Klein D, Velten M, Jégu J.

Ann Epidemiol. 2018 May;28(5):322-327. doi: 10.1016/j.annepidem.2018.02.008. Epub 2018 Feb 15.

PMID:
29550348
12.

The Champagne sign.

Minault Q, Gaiddon C, Veillon F, Venkatasamy A.

Abdom Radiol (NY). 2018 Oct;43(10):2888-2889. doi: 10.1007/s00261-018-1544-x. Review. No abstract available.

PMID:
29525879
13.

Holographic Traction Force Microscopy.

Makarchuk S, Beyer N, Gaiddon C, Grange W, Hébraud P.

Sci Rep. 2018 Feb 14;8(1):3038. doi: 10.1038/s41598-018-21206-2.

14.

Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action.

Babak MV, Pfaffeneder-Kmen M, Meier-Menches SM, Legina MS, Theiner S, Licona C, Orvain C, Hejl M, Hanif M, Jakupec MA, Keppler BK, Gaiddon C, Hartinger CG.

Inorg Chem. 2018 Mar 5;57(5):2851-2864. doi: 10.1021/acs.inorgchem.7b03210. Epub 2018 Feb 14.

PMID:
29442506
15.

Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma?

Manfredelli S, Delhorme JB, Venkatasamy A, Gaiddon C, Brigand C, Rohr S, Romain B.

Ann Surg Oncol. 2017 Oct;24(11):3324-3330. doi: 10.1245/s10434-017-5945-9. Epub 2017 Jun 26.

PMID:
28653159
16.

Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies.

Chow MJ, Alfiean M, Pastorin G, Gaiddon C, Ang WH.

Chem Sci. 2017 May 1;8(5):3641-3649. doi: 10.1039/c7sc00497d. Epub 2017 Feb 28.

17.

A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Licona C, Spaety ME, Capuozzo A, Ali M, Santamaria R, Armant O, Delalande F, Van Dorsselaer A, Cianferani S, Spencer J, Pfeffer M, Mellitzer G, Gaiddon C.

Oncotarget. 2017 Jan 10;8(2):2568-2584. doi: 10.18632/oncotarget.13711.

18.

Monomeric Ti(iv)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities.

Khalil G, Orvain C, Fang L, Barloy L, Chaumont A, Gaiddon C, Henry M, Kyritsakas N, Mobian P.

Dalton Trans. 2016 Nov 29;45(47):19072-19085.

PMID:
27858023
19.

The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton.

Platet N, Hinkel I, Richert L, Murdamoothoo D, Moufok-Sadoun A, Vanier M, Lavalle P, Gaiddon C, Vautier D, Freund JN, Gross I.

Cancer Lett. 2017 Feb 1;386:57-64. doi: 10.1016/j.canlet.2016.10.040. Epub 2016 Nov 2.

PMID:
27816490
20.

Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells.

Rico Bautista H, Saavedra Díaz RO, Shen LQ, Orvain C, Gaiddon C, Le Lagadec R, Ryabov AD.

J Inorg Biochem. 2016 Oct;163:28-38. doi: 10.1016/j.jinorgbio.2016.07.014. Epub 2016 Jul 26.

PMID:
27513948
21.

Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance.

Chow MJ, Licona C, Pastorin G, Mellitzer G, Ang WH, Gaiddon C.

Chem Sci. 2016 Jul 1;7(7):4117-4124. doi: 10.1039/c6sc00268d. Epub 2016 Mar 1.

22.

Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.

Chow MJ, Babak MV, Wong DY, Pastorin G, Gaiddon C, Ang WH.

Mol Pharm. 2016 Jul 5;13(7):2543-54. doi: 10.1021/acs.molpharmaceut.6b00348. Epub 2016 May 31.

PMID:
27174050
23.

Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63.

von Grabowiecki Y, Abreu P, Blanchard O, Palamiuc L, Benosman S, Mériaux S, Devignot V, Gross I, Mellitzer G, Gonzalez de Aguilar JL, Gaiddon C.

Elife. 2016 Feb 26;5. pii: e10528. doi: 10.7554/eLife.10528.

24.

Gold-phosphine-porphyrin as potential metal-based theranostics.

Tasan S, Licona C, Doulain PE, Michelin C, Gros CP, Le Gendre P, Harvey PD, Paul C, Gaiddon C, Bodio E.

J Biol Inorg Chem. 2015 Jan;20(1):143-54. doi: 10.1007/s00775-014-1220-8. Epub 2014 Dec 5.

PMID:
25476859
25.

Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy.

von Grabowiecki Y, Licona C, Palamiuc L, Abreu P, Vidimar V, Coowar D, Mellitzer G, Gaiddon C.

J Pharmacol Exp Ther. 2015 Jan;352(1):23-32. doi: 10.1124/jpet.114.216879. Epub 2014 Oct 17.

PMID:
25326132
26.

Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.

Chow MJ, Licona C, Yuan Qiang Wong D, Pastorin G, Gaiddon C, Ang WH.

J Med Chem. 2014 Jul 24;57(14):6043-59. doi: 10.1021/jm500455p. Epub 2014 Jul 15.

PMID:
25023617
27.

Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters.

Klajner M, Licona C, Fetzer L, Hebraud P, Mellitzer G, Pfeffer M, Harlepp S, Gaiddon C.

Inorg Chem. 2014 May 19;53(10):5150-8. doi: 10.1021/ic500250e. Epub 2014 May 1.

PMID:
24786362
28.

Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes.

Boff B, Gaiddon C, Pfeffer M.

Inorg Chem. 2013 Mar 4;52(5):2705-15. doi: 10.1021/ic302779q. Epub 2013 Feb 21.

PMID:
23427955
29.

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L.

J Med Chem. 2012 Nov 26;55(22):10064-73. doi: 10.1021/jm301201z. Epub 2012 Oct 23.

PMID:
23072299
30.

Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity.

Vidimar V, Meng X, Klajner M, Licona C, Fetzer L, Harlepp S, Hébraud P, Sidhoum M, Sirlin C, Loeffler JP, Mellitzer G, Sava G, Pfeffer M, Gaiddon C.

Biochem Pharmacol. 2012 Dec 1;84(11):1428-36. doi: 10.1016/j.bcp.2012.08.022. Epub 2012 Sep 1.

PMID:
22964219
31.

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G.

J Inorg Biochem. 2012 Jan;106(1):90-9. doi: 10.1016/j.jinorgbio.2011.09.030. Epub 2011 Sep 29. Review.

PMID:
22112845
32.

Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons.

Benosman S, Meng X, Von Grabowiecki Y, Palamiuc L, Hritcu L, Gross I, Mellitzer G, Taya Y, Loeffler JP, Gaiddon C.

J Biol Chem. 2011 Dec 16;286(50):43013-25. doi: 10.1074/jbc.M111.261271. Epub 2011 Oct 14.

33.

Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.

Fetzer L, Boff B, Ali M, Xiangjun M, Collin JP, Sirlin C, Gaiddon C, Pfeffer M.

Dalton Trans. 2011 Sep 21;40(35):8869-78. doi: 10.1039/c1dt10322a. Epub 2011 Aug 12.

PMID:
21837342
34.

Novel flavaglines displaying improved cytotoxicity.

Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Désaubry L.

J Med Chem. 2011 Jan 13;54(1):411-5. doi: 10.1021/jm101318b. Epub 2010 Dec 13.

PMID:
21142180
35.

DNA binding to an anticancer organo-ruthenium complex.

Klajner M, Hebraud P, Sirlin C, Gaiddon C, Harlepp S.

J Phys Chem B. 2010 Nov 11;114(44):14041-7. doi: 10.1021/jp1044783.

PMID:
20961087
36.

A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP.

Meng X, Leyva ML, Jenny M, Gross I, Benosman S, Fricker B, Harlepp S, Hébraud P, Boos A, Wlosik P, Bischoff P, Sirlin C, Pfeffer M, Loeffler JP, Gaiddon C.

Cancer Res. 2009 Jul 1;69(13):5458-66. doi: 10.1158/0008-5472.CAN-08-4408. Epub 2009 Jun 23.

37.

Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.

Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y, Okamoto K.

Cancer Sci. 2009 Jul;100(7):1291-9. doi: 10.1111/j.1349-7006.2009.01180.x. Epub 2009 Apr 27.

38.

Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis.

Benosman S, Gross I, Clarke N, Jochemsen AG, Okamoto K, Loeffler JP, Gaiddon C.

Cell Death Differ. 2007 Dec;14(12):2047-57. Epub 2007 Sep 7.

39.

Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival.

Gross I, Armant O, Benosman S, de Aguilar JL, Freund JN, Kedinger M, Licht JD, Gaiddon C, Loeffler JP.

Cell Death Differ. 2007 Oct;14(10):1802-12. Epub 2007 Jun 29.

40.

p53 and p73 display common and distinct requirements for sequence specific binding to DNA.

Lokshin M, Li Y, Gaiddon C, Prives C.

Nucleic Acids Res. 2007;35(1):340-52. Epub 2006 Dec 14.

41.

Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms.

Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP.

J Pharmacol Exp Ther. 2005 Dec;315(3):1403-11. Epub 2005 Sep 16.

PMID:
16169939
42.

Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation.

Gross I, Lhermitte B, Domon-Dell C, Duluc I, Martin E, Gaiddon C, Kedinger M, Freund JN.

Oncogene. 2005 Dec 1;24(54):7955-63.

PMID:
16027724
43.

Tissue specificity and regulation of the N-terminal diversity of reticulon 3.

Di Scala F, Dupuis L, Gaiddon C, De Tapia M, Jokic N, Gonzalez de Aguilar JL, Raul JS, Ludes B, Loeffler JP.

Biochem J. 2005 Jan 1;385(Pt 1):125-34.

44.

Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73.

Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, Prives C.

J Biol Chem. 2003 Jul 25;278(30):27421-31. Epub 2003 Apr 3.

45.
46.

Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein.

Boutillier AL, Gaiddon C, Lorang D, Roberts JL, Loeffler JP.

Pituitary. 1998 Apr;1(1):33-43.

PMID:
11081181
47.

Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway.

González de Aguilar JL, Gordon JW, René F, de Tapia M, Lutz-Bucher B, Gaiddon C, Loeffler JP.

Neurobiol Dis. 2000 Aug;7(4):406-15.

PMID:
10964611
48.

Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo.

Gaiddon C, Moorthy NC, Prives C.

EMBO J. 1999 Oct 15;18(20):5609-21.

49.

Brain-derived neurotrophic factor exerts opposing effects on beta2-adrenergic receptor according to depolarization status of cerebellar neurons.

Gaiddon C, Larmet Y, Trinh E, Boutillier AL, Sommer B, Loeffler JP.

J Neurochem. 1999 Oct;73(4):1467-76.

50.

The retinoblastoma susceptibility gene product/Sp1 signalling pathway is modulated by Ca2+/calmodulin kinases II and IV activity.

Sohm F, Gaiddon C, Antoine M, Boutillier AL, Loeffler JP.

Oncogene. 1999 Apr 29;18(17):2762-9.

Supplemental Content

Loading ...
Support Center